Sources say Pfizer (PFE) will delay a sale of its infant-nutrition division in order to study if...

|By:, SA News Editor

Sources say Pfizer (PFE) will delay a sale of its infant-nutrition division in order to study if a tax-free spinoff to investors provides more value. If the firm decides to proceed with the sale, firms reported to be in line to bid as high as $10.5B include Abbott Laboratories (ABT), Nestle (NSRGY.PK) and Danone (DANOY.PK).